drugset / Trial / NCT07014410
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a a multicenter Phase II clinical study investigating efficacy of pyrotinib combined with dalpiciclib combined with letrozole in ER-positive and HER2-positive advanced breast cancer patients. The sample size is 63.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 125 mg | — |
| Subject | Letrozole | Other / unclassified | 2.5 mg | — |
| Subject | Pyrotinib | Small molecule | 320 mg | — |